Friday, July 10, 2026

pharma · Eosinophilic esophagitis · Narcolepsy

Bioprojet

Bioprojet Pharma is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Eosinophilic esophagitis, Narcolepsy, narcolepsy with cataplexy, Narcolepsy, Narcolepsy, Narcolepsy with catap

9 rue Rameau, Paris, 75002, FR HQ
166 Employees
EMA registrant Type
Company details
Status
Public
HQ
9 rue Rameau, Paris, 75002, FR
Employees
166
Programs
11
Drugs
19
Patents
9

Quick answer

Bioprojet Pharma is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Eosinophilic esophagitis, Narcolepsy, narcolepsy with cataplexy, Narcolepsy, Narcolepsy, Narcolepsy with cataplexy, Essential tremor. NovaPharmaNews links 11 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (6), phase 2 (4), phase 3 (1).

Company snapshot

Bioprojet is a pharmaceutical laboratory committed to science and health. In the last 40 years, we’ve brought forward breakthrough medicines, helping patients struggling with challenging diseases. With passion and integrity, we follow the path set by Jeanne-Marie Lecomte and Jean-Charles Schwartz, founders of Bioprojet. At Bioprojet, we grow to keep honoring our motto : Passion for Research. Resea

  • 11 active pipeline program(s) linked via ClinicalTrials.gov.
  • 9 US patent(s) indexed to this assignee profile.
  • 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bioprojet. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Bioprojet.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Bioprojet.

  1. Clinical update

    P23-01 — Phase 1

  2. Clinical update

    P25-01 — Phase 1

  3. Clinical update

    P24-06 — Phase 1

  4. Clinical update

    P24-03 — Phase 1

  5. Clinical update

    P22-03 — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Bioprojet?

    Bioprojet Pharma is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Eosinophilic esophagitis, Narcolepsy, narcolepsy with cataplexy, Narcolepsy, Narcolepsy, Narcolepsy with cataplexy, Essential tremor. NovaPharmaNews links 11 clinical pro

  • Is Bioprojet publicly traded?

    Bioprojet appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Bioprojet develop or market?

    We link 19 drug profile(s) where Bioprojet is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bioprojet-pharma#company-drugs.

  • What are the latest developments for Bioprojet?

    In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Bioprojet focus on?

    Bioprojet focuses on Eosinophilic esophagitis, Narcolepsy, narcolepsy with cataplexy, Narcolepsy based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
22
Cardiology
1
Neurology
1